Google Alert - "LSD1 inhibitor" OR "sickle cell disease" · Scour

Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary ...

Novo Nordisk Shows Sickle Cell Efficacy Advantage Over Agios's Mitapivat

Sex- and Race-Based Disparities Seen in Provider Diagnosis of IBS

Interdisciplinary Care is a Promising Approach for Pediatric Patients with Long-COVID

What a decade of gene therapy research for sickle cell disease taught UCLA scientists

Here's Why Agios Pharmaceuticals Crashed 23% Today

Positive Phase 3 Results for Novo Nordisk (NVO) in Sickle Cell Disease Treatment

Etavopivat Reduces VOCs and Boosts Hemoglobin in Sickle Cell Disease

Novo Nordisk Eyes Rare Disease Growth As Etavopivat Phase 3 Succeeds

Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock

Backed by Peter Thiel and OpenAI, Toronto startup Biossil aims to give failed drugs new life with AI

Novo Nordisk to seek oral sickle cell therapy approval after Phase III victory

What a decade of gene therapy research for sickle cell disease taught UCLA scientists

Decade of Gene Therapy Unveils Sickle Cell Insights

Clinician Notes for Sickle Cell Patients Often Include High Number of Negative Descriptors

Novo Nordisk touts Phase III success for etavopivat

Biotech has become a good news story. Let the sun shine

Novo's Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%.

Agios Pharmaceuticals stock tumbles 25% after Novo data

Interdisciplinary Care is a Promising Approach for Pediatric Patients with Long-COVID

Log in to enable infinite scrolling